Zydus’ generic of hormone therapy patch gets U.S. FDA nod
The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S. Federal Food, Drug, and Cosmetic Act.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - October 21, 2026 05:58 pm IST - HYDERABAD
Zydus Lifesciences has received final approval from the U.S.
Food and Drug Administration (FDA) for its abbreviated new drug application for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day.
Bayer’s Climara Pro Transdermal System 0.045 mg/0.015 mg per day is the reference listed drug for the product.
Estradiol and Levonorgestrel Transdermal System, which is primarily used to treat moderate to severe symptoms of menopause, had annual sales of around $45.7 million in the U.S., Zydus said citing IQVIA MAT Aug-2026 numbers.
The ANDA has been designated by the U.S.
FDA as a competitive generic therapy.
The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S.
Federal Food, Drug, and Cosmetic Act.
The product, also used in postmenopausal women for prevention of osteoporosis, will be manufactured at the group’s manufacturing plant near Ahmedabad, the company said.
business (general) / pharmaceutical / medicine / generic drugs / research / medical research / USA
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
